<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412371</url>
  </required_header>
  <id_info>
    <org_study_id>M14-360</org_study_id>
    <nct_id>NCT02412371</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in
      combination with concurrent Paclitaxel/Carboplatin-based chemoradiotherapy (Phase 1 portion)
      and to assess whether the addition of oral veliparib versus placebo to
      Paclitaxel/Carboplatin-based chemoradiotherapy with Paclitaxel/Carboplatin consolidation
      will improve progression-free survival (PFS) in subjects with Stage III non-small cell lung
      cancer (Phase 2 portion).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RPTD) of veliparib (ABT-888) in combination with radiotherapy, paclitaxel and carboplatin</measure>
    <time_frame>Approximately 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Recommended Phase 2 dose (RPTD) in combination with radiotherapy, paclitaxel and carboplatin will be determined by dose escalation in phase 1 of the study. Dose limiting toxicity (DLT) events will be collected for each dosing cohort until a new dosing cohort is opened or until the recommended Phase 2 dose is identified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS) is defined as the number of days from the date of enrollment to the date of earliest progression or death. If the participant does not experience disease progression or death, then the data will be censored at the date of the last disease assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival is defined as the number of days from the date of participant enrollment to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately every 8 weeks from first dose until one year after beginning therapy, then every 12 weeks for up to 3 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective Response Rate (ORR) is defined as the proportion of the participants who have a complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response (DOR)</measure>
    <time_frame>Approximately every 8 weeks from first dose until one year after beginning therapy, then every 12 weeks for up to 3 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of Overall Response (DOR) is defined as the time from the participant's initial CR or PR to the time of disease progression.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Until a participant achieves 1 year on treatment (for participants in phase 2 only)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Two short cancer questionnaires by the European Organization for Research and Treatment of Cancer (EORTC) will be used to measure change in a participant's quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in ECOG (Eastern Cooperative Oncology Group) Performance Status of Participants</measure>
    <time_frame>Approximately 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Non-small Cell Lung Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + veliparib followed by consolidation of Carbo/Pac + veliparib, is for both the Phase 1/dose escalation and Phase 2 portion of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + veliparib followed by consolidation of Carbo/Pac + Placebo, is for the Phase 2 portion of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + placebo followed by consolidation of Carbo/Pac + placebo, is for the Phase 2 portion of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Oral capsule of varying doses</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered via intravenous infusion on Day 1 of each treatment week/cycle.</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered via intravenous infusion on Day 1 of each treatment week/cycle.</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiation treatment administered on Day 1 through Day 5 of each week for approximately 30-34 visits.</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for Veliparib</intervention_name>
    <description>Oral capsule of varying doses</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants with Histologically or cytologically confirmed Stage III non-small cell
             lung cancer (NSCLC).

          2. Participants in the randomized portion of the study must have measurable disease per
             Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.

          3. Participants must have V20 (volume of lung to receive 20 Gy radiotherapy according to
             simulation) &lt; 35%.

          4. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score
             of 0 - 1.

          5. Participant must have adequate hematologic, renal, hepatic, and lung function.

        Exclusion Criteria:

          1. Participants with prior chemotherapy or radiotherapy (RT) for current NSCLC.
             Participants curatively treated for past early stage NSCLC greater than 3 years ago
             may be included.

          2. Participants with prior exposure to poly-ADP-ribose polymerase (PARP) inhibitors.

          3. Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations
             containing polyethoxylated castor oil (Cremophor).

          4. Participants with prior mediastinal or thoracic radiotherapy. Prior tangential RT to
             prior breast cancer is acceptable.

          5. Participants with major surgery in the 4 weeks prior to randomization (Video-assisted
             thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery).

          6. Participants with a previous or concurrent malignancy except for treated basal cell
             or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
             patient received potentially curative treatment and has been disease-free for 3 years
             or is considered cured by the investigator if has been disease-free for less than 3
             years.

          7. Participant is pregnant or lactating.

          8. Participant with sensory peripheral neuropathy of â‰¥ Grade 2 at baseline, unable to
             swallow medication, or participants with prior history of seizure within the prior 12
             months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent L Giranda, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark D McKee, MD</last_name>
    <phone>847-937-2828</phone>
    <email>mark.mckee@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindsey M Bensman, BS</last_name>
    <phone>847-935-1821</phone>
    <email>lindsey.bensman@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133037</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133037, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133486</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133486, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133828</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133828, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132944</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132944, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133494</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133494, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133492</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133492, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134438</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134438, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133496</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133496, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133497</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133497, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134608</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134608, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133493</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133493, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133910</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133910, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141321</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133495</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133495, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 20, 2016</lastchanged_date>
  <firstreceived_date>November 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>previously untreated</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>ABT-888</keyword>
  <keyword>stage III</keyword>
  <keyword>first line</keyword>
  <keyword>carboplatin</keyword>
  <keyword>veliparib</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
